Supreme Court’s concerns over medicine mark-ups and renewed focus on private healthcare pricing trigger selling across hospital counters

Shares of listed hospital companies came under sharp selling pressure on Wednesday, September 30, with Apollo Hospitals Enterprise, Fortis Healthcare, Max Healthcare Institute and Yatharth Hospital & Trauma Care Services among the major decliners. The selling came amid reports that the Supreme Court has raised concerns over the large gap between the price to retailer (PTR) and maximum retail price (MRP) of essential medicines sold to patients, particularly through hospital pharmacies.

The development has revived investor concerns about the possibility of tighter pricing oversight across parts of the private healthcare ecosystem. The BSE Sensex, in contrast, was trading higher in early deals, highlighting that the pressure was concentrated in the hospital segment rather than being part of a broad market sell-off.

Hospital stocks see heavy selling

Among individual counters, Max Healthcare Institute fell as much as 7 per cent to around ₹915 on the BSE, moving close to its 52-week low of ₹903.50 recorded in April.

Apollo Hospitals Enterprise declined around 6 per cent to ₹8,158.55 in the initial trading session, while Fortis Healthcare also dropped around 6 per cent to ₹772.70, close to its 52-week low of ₹767.30.

Yatharth Hospital & Trauma Care Services and Aster DM Healthcare were down around 5 per cent each, while Krishna Institute of Medical Sciences and Global Health, which operates the Medanta hospital network, declined around 4 per cent.

The intensity of the moves indicates that investors are reassessing the potential earnings implications of any future intervention in medicine pricing, hospital billing or other components of healthcare charges.

Supreme Court flags medicine pricing gap

The immediate trigger was the Supreme Court's reported concern over the difference between the price at which medicines reach retailers and the MRP ultimately charged to patients.

Reports cited an example involving a cancer medicine with a PTR of roughly ₹2,700 but an MRP of about ₹27,000. The Court questioned the rationale for such a large difference and discussed whether a uniform margin framework could be considered for medicines.

The Court's observations are particularly significant for private hospitals because medicines and other consumables can form an important component of patient bills, especially in complex treatments and prolonged hospitalisation.

However, the Court's observations should not be interpreted as an immediate nationwide price cap. Any change to the existing regulatory framework would require appropriate government and regulatory action.

What does the existing 16% margin rule mean?

The 16 per cent figure discussed in the latest reports is linked to the existing Drugs (Prices Control) Order, 2013.

Under the DPCO framework, the ceiling price of scheduled medicines is calculated using market-based pricing and a 16 per cent retailer margin is added to the average price to retailer. The National Pharmaceutical Pricing Authority (NPPA) currently regulates the ceiling prices of medicines included under the price-control framework.

Importantly, the existing framework does not mean that every medicine sold in India carries a universally regulated 16 per cent margin across the entire supply chain. Government documents distinguish between scheduled and non-scheduled formulations, while margins at different levels of the distribution chain can vary according to commercial arrangements.

This distinction is important for investors because the potential impact on hospital companies would depend on the exact scope and implementation of any future regulatory measure.

Why hospital pharmacies matter to investors

Hospital operators can generate revenue from multiple streams, including inpatient treatment, outpatient services, diagnostics, surgeries, consultations, medical procedures, pharmacy sales and other healthcare services.

Therefore, a regulatory change affecting medicine mark-ups would not automatically translate into an equivalent reduction in overall hospital revenue or profitability.

The potential financial impact would instead depend on factors such as the proportion of pharmacy revenue, the share of medicines dispensed internally, procurement costs, reimbursement structures, patient mix and the ability of hospitals to adjust other charges.

For large integrated hospital chains, pharmacy operations can also be strategically important because they are connected to the overall patient-care ecosystem.

Regulatory pressure is not limited to medicines

The latest development comes against the backdrop of a broader debate over the affordability and transparency of private healthcare.

In August, the Parliamentary Standing Committee on Health and Family Welfare recommended that basic room charges at private hospitals in large metropolitan areas should not exceed the average tariff of nearby three-star hotels. The committee also proposed greater transparency in billing, upfront cost estimates for complex treatments and standardised package rates for medical and surgical procedures.

These recommendations are not automatically binding on private hospitals. They would require government consideration and appropriate regulatory action before becoming enforceable.

The broader message for the healthcare sector, however, is that affordability, transparency and pricing are receiving increasing policy attention.

Apollo and Fortis already carry regulatory sensitivity

Healthcare companies have historically faced regulatory intervention in areas such as medical devices, treatment pricing, reimbursement rates and healthcare charges.

Apollo Hospitals has previously highlighted regulatory risks including possible price controls on procedures and consumables, changes in reimbursement rates under government healthcare schemes and greater oversight of hospital tariffs. Rating agencies have also noted that such measures could affect revenue growth, margins and cash flows.

Fortis Healthcare faces similar sector-level risks. Regulatory changes affecting treatment pricing, medical devices, reimbursement structures or hospital billing can influence the economics of private healthcare operators.

The experience with earlier price controls on products such as cardiac stents and knee implants also demonstrates why investors closely track policy developments affecting healthcare pricing.

Hospital sector fundamentals remain important

The selling pressure does not necessarily change the underlying demand outlook for healthcare services.

India continues to face a substantial need for additional hospital capacity, specialised treatment facilities and high-quality tertiary healthcare. Rising health awareness, increasing insurance penetration, ageing demographics, medical tourism and the expansion of organised healthcare networks remain important structural themes for the sector.

For hospital chains, growth can come from adding beds, increasing occupancy, expanding into new cities, improving case mix, increasing high-end procedures and expanding diagnostics and other ancillary services.

Consequently, investors will need to distinguish between short-term regulatory concerns and the longer-term demand opportunity.

The key question is the scope of any future regulation

The immediate market reaction reflects uncertainty rather than a confirmed earnings impact.

A broad cap on medicine margins could affect hospitals differently depending on their pharmacy mix and business model. A narrower framework covering only certain essential medicines would have a different impact from a comprehensive regulation covering hospital pharmacies, room charges, procedures and consumables.

Investors will therefore watch for clarification from the government, the Ministry of Health and Family Welfare, the Department of Pharmaceuticals and the NPPA regarding the next steps following the Supreme Court's observations.

What investors should monitor

For listed hospital companies, the key factors to track will include:

• Any formal government proposal on medicine pricing or hospital pharmacy margins

• Clarification on whether proposed measures cover hospital pharmacies specifically

• The treatment of scheduled and non-scheduled medicines

• Possible regulation of private hospital room charges

• Standardisation of treatment packages and billing

• Reimbursement rates under government healthcare schemes

• Hospital occupancy and average revenue per occupied bed

• Pharmacy revenue contribution and margins

• Expansion plans and new-bed additions

• Regulatory developments affecting medical devices and consumables

The eventual financial impact will depend on the design and implementation of any policy rather than the Supreme Court's observations alone.

Market Outlook

Hospital stocks are likely to remain sensitive to regulatory headlines in the near term as investors assess whether concerns around medicine pricing could translate into concrete policy measures.

The immediate fall in Apollo Hospitals, Fortis Healthcare, Max Healthcare and Yatharth Hospital reflects heightened uncertainty over potential pressure on pricing and margins. However, the companies have diversified revenue streams and their long-term performance will also depend on occupancy, capacity expansion, case mix, healthcare demand and operating efficiency.

For investors tracking the sector, the next important trigger is likely to be clarity on whether the current discussion remains an observation by the Supreme Court or develops into a formal regulatory framework. Until then, stock-specific fundamentals and the eventual scope of any pricing intervention are likely to remain the key variables for hospital-sector valuations.